The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | A Phase I trial of ex vivo expanded donor gamma delta T-cells to prevent AML relapse after alloSCT
Marco Davila, MD, PhD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, comments on the development and early results of a Phase I clinical trial using gamma delta T-cells to treat patients with acute myeloid leukemia (AML) following allogeneic stem cell transplantation (alloSCT). Dr Davila highlights that gamma delta T-cells are sensitive to leukemia cells and will hopefully enable remission to be maintained post-alloSCT in patients at high risk for relapse. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So this is a great collaboration with Dr Nelli Bejanyan from the Moffitt Cancer Center. So what I did is developed a production system to be able to efficiently and rapidly expand gamma delta T-cells from patients. And what Dr Bejanyan has done is taken that and developed a Phase I clinical trial to put those gamma delta T-cells into patients post-allogeneic stem cell transplant, those patients that are at high risk for relapse...
So this is a great collaboration with Dr Nelli Bejanyan from the Moffitt Cancer Center. So what I did is developed a production system to be able to efficiently and rapidly expand gamma delta T-cells from patients. And what Dr Bejanyan has done is taken that and developed a Phase I clinical trial to put those gamma delta T-cells into patients post-allogeneic stem cell transplant, those patients that are at high risk for relapse. And relapse is the number one killer of patients post-allogeneic transplant. So the idea behind this is that gamma-deltas are very sensitive to diseased cells and cancer cells such as leukemia cells. And the idea is that we’re gonna improve the ability of these patients to be cured by allogeneic transplants. So about nine patients have been treated so far. We’ve shown that this is safe and actually able to maintain remissions in these patients at high risk for relapse.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
